August 02, 2019 Strike two for overheated South Korean biotech Pexa-Vec fails earlier than expected, dealing exuberant South Korean biotech investors and the oncolytic virus field another blow.
April 04, 2019 Sillajen and Transgene bid to revive the oncolytic virus craze The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
